Limits...
Colorectal cancer and NF-κB signaling pathway.

Hassanzadeh P - Gastroenterol Hepatol Bed Bench (2011)

Bottom Line: However, many cases show that tolerance develops to such treatments; therefore, new strategies are required to replace or complement current therapies.Nuclear factor-κB (NF-κB) transcription factors play a key role in many physiological processes such as innate and adaptive immune responses, cell proliferation, cell death, and inflammation.Hence, anti-NF-κB therapy may rescue many cases of CRC and should be considered as a therapeutic target.

View Article: PubMed Central - PubMed

Affiliation: Research Institute for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ABSTRACT
Colorectal cancer (CRC) is the second leading cause of cancer death. Progress has been made in the development of chemotherapy for advanced CRC. Targeted therapies against VEGF or EGFR are now commonly used. However, many cases show that tolerance develops to such treatments; therefore, new strategies are required to replace or complement current therapies. Nuclear factor-κB (NF-κB) transcription factors play a key role in many physiological processes such as innate and adaptive immune responses, cell proliferation, cell death, and inflammation. It has become clear that aberrant regulation of NF-κB and the signaling pathways that control its activity are involved in cancer development and progression, as well as in resistance to chemo- and radio- therapies. Hence, anti-NF-κB therapy may rescue many cases of CRC and should be considered as a therapeutic target.

No MeSH data available.


Related in: MedlinePlus

Proteasome degradation cycle
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4017424&req=5

Figure 0003: Proteasome degradation cycle

Mentions: The proteasome is a 26S multiprotein complex that is mainly located in the cytoplasm and nucleus. It consists of a 19S regulatory subunit and a 20S catalytic subunit that contains six unique ATP-dependent serine protease sites, two of each with chymotrypsin, trypsin, and caspase-like activities (32, 33) (Figure 3).


Colorectal cancer and NF-κB signaling pathway.

Hassanzadeh P - Gastroenterol Hepatol Bed Bench (2011)

Proteasome degradation cycle
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4017424&req=5

Figure 0003: Proteasome degradation cycle
Mentions: The proteasome is a 26S multiprotein complex that is mainly located in the cytoplasm and nucleus. It consists of a 19S regulatory subunit and a 20S catalytic subunit that contains six unique ATP-dependent serine protease sites, two of each with chymotrypsin, trypsin, and caspase-like activities (32, 33) (Figure 3).

Bottom Line: However, many cases show that tolerance develops to such treatments; therefore, new strategies are required to replace or complement current therapies.Nuclear factor-κB (NF-κB) transcription factors play a key role in many physiological processes such as innate and adaptive immune responses, cell proliferation, cell death, and inflammation.Hence, anti-NF-κB therapy may rescue many cases of CRC and should be considered as a therapeutic target.

View Article: PubMed Central - PubMed

Affiliation: Research Institute for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ABSTRACT
Colorectal cancer (CRC) is the second leading cause of cancer death. Progress has been made in the development of chemotherapy for advanced CRC. Targeted therapies against VEGF or EGFR are now commonly used. However, many cases show that tolerance develops to such treatments; therefore, new strategies are required to replace or complement current therapies. Nuclear factor-κB (NF-κB) transcription factors play a key role in many physiological processes such as innate and adaptive immune responses, cell proliferation, cell death, and inflammation. It has become clear that aberrant regulation of NF-κB and the signaling pathways that control its activity are involved in cancer development and progression, as well as in resistance to chemo- and radio- therapies. Hence, anti-NF-κB therapy may rescue many cases of CRC and should be considered as a therapeutic target.

No MeSH data available.


Related in: MedlinePlus